Clark Estates Inc. NY Sells 31,000 Shares of Bausch + Lomb Co. (NYSE:BLCO)

Clark Estates Inc. NY reduced its position in shares of Bausch + Lomb Co. (NYSE:BLCO) by 4.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 687,500 shares of the company’s stock after selling 31,000 shares during the period. Bausch + Lomb makes up approximately 2.5% of Clark Estates Inc. NY’s investment portfolio, making the stock its 9th biggest position. Clark Estates Inc. NY’s holdings in Bausch + Lomb were worth $13,262,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Blue Trust Inc. increased its position in Bausch + Lomb by 14,052.2% during the 2nd quarter. Blue Trust Inc. now owns 3,255 shares of the company’s stock worth $47,000 after purchasing an additional 3,232 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Bausch + Lomb during the second quarter worth $173,000. Renaissance Capital LLC increased its holdings in shares of Bausch + Lomb by 57.2% during the second quarter. Renaissance Capital LLC now owns 36,286 shares of the company’s stock worth $527,000 after buying an additional 13,210 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Bausch + Lomb by 80.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 29,755 shares of the company’s stock valued at $576,000 after acquiring an additional 13,302 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in Bausch + Lomb during the 2nd quarter worth $580,000. Institutional investors and hedge funds own 11.07% of the company’s stock.

Bausch + Lomb Stock Up 0.4 %

NYSE:BLCO opened at $19.75 on Wednesday. The firm has a fifty day simple moving average of $19.78 and a two-hundred day simple moving average of $17.07. Bausch + Lomb Co. has a 12 month low of $13.16 and a 12 month high of $21.69. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings data on Wednesday, October 30th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.01. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The business’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same period last year, the firm earned $0.22 earnings per share. As a group, sell-side analysts expect that Bausch + Lomb Co. will post 0.59 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on BLCO. Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a report on Thursday, October 31st. Evercore ISI upgraded Bausch + Lomb from an “in-line” rating to an “outperform” rating and upped their price target for the company from $19.00 to $25.00 in a research report on Tuesday, October 15th. Deutsche Bank Aktiengesellschaft upped their target price on Bausch + Lomb from $14.00 to $18.00 and gave the company a “hold” rating in a report on Thursday, August 1st. Stifel Nicolaus raised their price target on shares of Bausch + Lomb from $16.00 to $19.00 and gave the stock a “hold” rating in a report on Monday, September 23rd. Finally, HC Wainwright upped their price objective on shares of Bausch + Lomb from $22.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.91.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.